Evidence map›Paper›PMID 41152966›Full record

ArticleBMC palliative care2025

Mapping study on AI-based technologies in palliative care - a scoping study.

Mariana Silva-Ferreira, Sara Cruz, Michael Sapateiro Luís, Maria Cândida Silva, Sara Monteiro-Reis, Rui Henrique, Carmen Jerónimo, Saint-Clair Lefèvre, Ambre Laplaud, Matthieu Frasca and 8 more

Abstract readScoping Review
In one paragraph

Article in BMC palliative care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Palliative care and social practice · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mariana Silva-Ferreira *Cancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP) Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal.
Sara Cruz *CI-IPOP@RISE-Associate Laboratory and Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, Porto, Portugal.
Michael Sapateiro LuísDepartment of Palliative Care, Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal. michael.luis@ipoporto.min-saude.pt.
Maria Cândida SilvaDepartment of Palliative Care, Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal.
Sara Monteiro-ReisCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP) Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal.
Rui HenriqueCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP) Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal.
Carmen JerónimoCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP) Portuguese Oncology Institute of Porto (IPO Porto), R. Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal.
Saint-Clair LefèvreInfinitivity Design Labs (IDL), Haute Loire, Laussanne, France.
Ambre LaplaudGérontopôle Nouvelle-Aquitaine, Limoges, France.
Matthieu FrascaCHU de Bordeaux, Service d'accompagnement et de Médecine Palliative, Bordeaux, France.
Lucie PolletCHU de Bordeaux, Service d'accompagnement et de Médecine Palliative, Bordeaux, France.
Lourdes ZurbanobeaskoetxeaDiputación Foral de Bizkaia, Regional Government of Bizkaia, Bilbao, Bizkaia, Spain.
Rosana Angles BarbastroServicio Aragonés de Salud, Hospital de Barbastro, Barbastro, Spain.
María Isabel Hidalgo GarcíaConsejería de Familia e Igualdad de Oportunidades, Gerencia de Servicios Sociales (GSS), Valladolid, Spain.
Beatriz Jiménez GalánConsejería de Familia e Igualdad de Oportunidades, Gerencia de Servicios Sociales (GSS), Valladolid, Spain.
Fátima González PalauInstituto de Neurociencias y Bienestar, Universidad Siglo 21, Córdoba, Argentina.
Diana Filipa MarquesFundación INTRAS, Valladolid, Spain.
Raquel Losada DuránFundación INTRAS, Valladolid, Spain.

Funding

European Commission, in the component FEDER, trough Interreg VI-B South-West Europe S1/4.5/E0091
6 · The paper itself

Abstract

backgroundThe aging population and rising prevalence of chronic illnesses emphasize the importance of palliative care (PC), which focuses on enhancing patients' quality of life (QoL) while supporting their families and caregivers. PC integrates multidisciplinary interventions to alleviate the physical, psychological, social, and spiritual suffering of individuals facing serious or terminal illnesses. Concurrently, Artificial Intelligence (AI) advancements have been transforming the healthcare sector, particularly through Clinical Decision Support Systems (CDSS). Leveraged by advanced algorithms and machine learning (ML), these tools analyze large volumes of data to support diagnostics, personalized treatments, and early interventions. In PC, AI has demonstrated potential to enhance early diagnosis, identify support needs, and personalize end-of-life care. ML algorithms help predict symptoms and complications, enabling timely and effective interventions. However, challenges remain, including data privacy concerns, integration into clinical workflows, and ethical implications of AI in sensitive care contexts.

methodsWe conducted a scoping review to map and analyze AI applications on PC. Articles published until May 2024 were identified in two electronic databases. From 542 records, 57 studies met the inclusion criteria. The review explored trends, benefits, and limitations of AI applications, highlighting tools for diagnostic and prognostic support, symptom tracking, shared decision-making, and communication with patients and families.

resultsThe findings highlight how digital technologies and AI are revolutionizing communication, care coordination, and symptom control in PC, unlocking remote care options. The review identified key advancements in symptom management, communication, decision support, telemedicine and education areas, while addressing barriers like ethical, legal, and accessibility concerns.

conclusionsBy compiling evidence on AI use in PC, we aimed to empower professionals, researchers, and policymakers to promote more effective, ethical, and person-centered strategies. Ultimately, we provide insights for developing new technologies and establishing protocols that support the safe, equitable, and person-centered implementation of AI in palliative care, and highlight the need to prioritize early identification of patient needs, promote integration between hospital and community care, and establish protocols.

Indexed as

Artificial IntelligencePalliative CareHumansQuality of LifeArtificial IntelligenceDigital Health TechnologyPalliative CarePatient-Centered CareScoping Review

Identifiers

PMID41152966
PMCPMC12570659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.